Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Risk Classification Governs SUD Reprocessor Premarket Requirements - FDA

This article was originally published in The Gray Sheet

Executive Summary

FDA's current resource levels are insufficient to carry out inspections of health care facilities that reprocess medical devices intended for single use, FDA staffers believe.

You may also be interested in...



FDA Plans Revisions To Guidance For Categorizing SUD Reprocessing Risks

FDA currently intends to reissue by the end of January its scheme for categorizing the risk of reprocessing single-use devices (SUDs) as a level one guidance document, according to staffers.

FDA Plans Revisions To Guidance For Categorizing SUD Reprocessing Risks

FDA currently intends to reissue by the end of January its scheme for categorizing the risk of reprocessing single-use devices (SUDs) as a level one guidance document, according to staffers.

FDA Risk Categorization Plan Says SUDs With Narrow Lumens Are High Risk

Reprocessed single-use devices (SUDs) would be considered "high risk" under FDA's proposed categorization scheme if they include inaccessible parts, narrow lumens, rough or porous surfaces, interlocking parts or other features that impede their cleaning, disinfecting or sterilization, according to an agency draft guidance.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel